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ABSTRACT 
 
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by pancreatic β-cell destruction and 
considered to be correlated with oxidative stress. This study aimed to investigate the association of oxidative stress 
[superoxide dismutase (SOD) and malondialdehyde (MDA) levels], inflammation [interleukin 10 (IL-10)], and gly-
cemic control (HbA1c) in pediatric T1DM patients. This study included 25 T1DM subjects and 25 healthy control 
subjects and was designed as a cross- sectional study. SOD, MDA, and IL-10 levels were measured by ELISA. We 
obtained that that IL-10 and SOD levels were significantly decreased in the T1DM group, but MDA and HbA1c 
levels were significantly elevated in the T1DM group. IL-10 levels were positively correlated with SOD levels and 
negatively correlated with MDA and HbA1c. SOD levels were negatively correlated with HbA1c levels. MDA was 
positively correlated with HbA1c levels. IL-10 and SOD levels were significantly decreased, but MDA and HbA1c 
levels were significantly elevated in the T1DM group. 
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INTRODUCTION 
Type 1 diabetes mellitus (T1DM) is an autoimmune 
disease caused by pancreatic β-cell destruction as the re-
sult of several interacting factors, including genetic vul-
nerability and environmental exposure [1]. Ninety per-
cent of T1DM cases occur in children and adolescents. 
Its incidence varies worldwide, the highest being in the 
Finnish population (40 per 100 000 people), and the 
lowest in the Chinese population (0.1 per 100 000 peo-
ple per year) [2]. Data gathered from the Coordination 
Framework Unit of Pediatric Endocrinology, Indonesian 
Pediatric Association indicated a prevalence of T1DM 
was 731 cases in 2012 [3]. Other data from Saiful Anwar 
General Hospital, Malang showed that there were 35 
T1DM patients ranging in age from 1 to 18 years (2005-
2013) [4]. 
Destruction of pancreatic β cells is mediated by T-
cell hyperreactivity, which in turn induces the release of 
autoantibodies. Impaired immunoregulation causes T-
cell autoreactivity, then induces islet cell inflammation, 
and finally causes pancreatic β-cell destruction [3, 5]. 
A previous study showed that oxidative stress plays 
an important role in diminished insulin action and se-
cretion.  Oxidative stress in diabetic patients might be 
caused by decreased antioxidant enzyme activity and el-
evated reactive oxygen species (ROS) levels, which in 
turn cause further lipid peroxidation and glycation [6]. 
A previous study showed that decreased activity of sev-
eral enzymes, such as superoxide dismutase (SOD), pe-
roxidase (Px), ceruloplasmin (Cp), and glutathione pe-
roxidase (GSH-Px), as well as elevated glutathione di-
sulfide (GSSG), were present in erythrocytes and tissues 
from diabetic patients [7]. 
Interleukin 10 (IL-10) is an anti-inflammatory cyto-
kine with the ability to downregulate inflammatory cy-
tokine production and thus inhibit T-cell activation. IL-
10 is a potent inhibitor of Th1 cytokines, such as IL-2 
and IFN-γ. In T1DM, proinflammatory cytokines are 
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elevated and anti-inflammatory cytokines are decreased 
as compared with the nondiabetic individuals [8]. Gly-
cemic control is related to both microvascular and 
macrovascular complications. Good glycemic control 
could increase the quality of life of T1DM patients. High 
HbA1c levels reflect poor glycemic control [9]. 
To date, a study on the association of oxidative 
stress and inflammation status with glycemic control in 
T1DM patients in Indonesia has not been conducted. 
This study aimed to investigate the association of IL-10, 
SOD, and malondialdehyde (MDA) levels with HbA1c 
levels in pediatric T1DM patients. 
 
MATERIALS AND METHODS 
Study design 
A cross-sectional (observational, analytic) study was 
conducted to compare the levels of IL-10, SOD, and 
MDA with those of HbA1c in pediatric T1DM patients. 
All procedures were approved by the Research Ethics 
Committee of Saiful Anwar General Hospital, Malang. 
 
Subjects  
A total of 50 subjects were included in this research 
and divided equally into two groups (control and T1DM 
group). The inclusion criteria for subjects were as fol-
lows: diagnosed as T1DM, aged between 1 and 18 years 
old, and allowed by his/her parents to participate (in-
formed consent). The exclusion criteria for subjects were 
the following: T1DM patients who had other diseases, 
such as other autoimmune diseases, liver, and renal im-
pairment, and anemia and consumption of antioxidants  
within 3 weeks before the study. To establish good 
matching of subjects and controls, the inclusion criteria 
for controls were age between 1 and 18 years and al-
lowed by his/her parents to participate (informed con-
sent). The exclusion criteria for controls were T1DM pa-
tients; diagnosed with the autoimmune disease (such as 
SLE), severe infection, liver and/or renal impairment, or 
anemia; and consumption of antioxidants within 3 
weeks before the study. All subjects (control and T1DM 
group) were taken from the Pediatric Ward, Saiful 
Anwar General Hospital, Malang. 
 
Measurement of SOD 
SOD was measured by a competitive ELISA method 
as previously described. Briefly, blood samples to which 
EDTA was added were centrifuged at 1,000 rpm for 15 
minutes. A 50 µL volume of sample or standard was 
added to each well of a microtiter plate and an equal 
volume of biotinylated antibody was added and incu-
bated for 45 min at 37°C. After washing, 100 µL HRP 
conjugate was added to each well and then incubated for 
30 min at 37°C. After washing, 90 µL tetramethylbenzi-
dine (TMB) substrate was added to each well and then 
incubated for 15 minutes at 37°C.  Finally, 50 µL stop 
solution was added and 30 minutes later, the absorbance 
was read in a microplate reader at 450 nm. SOD meas-
urements were conducted at the Physiology Laboratory, 
Medical Faculty of Brawijaya University, Malang. 
 
Table 1.  Subject characteristics 
Characteristics Control (n = 25) Mean ± SD DM (n = 25) Mean ± SD 
Sex:   
Male 9 10 
Female  16 15 
Age 10.04 ± 3.43 11.48 ± 2.60 
%IBW 90.52 ± 5.15 93.34 ± 8.83 
Erythrocyte count (/μL) 5.12 ± 0.53 5.22 ± 0.54 
Leucocyte count (/μL) 8,747 ± 929.79 8,920.40 ± 715.74 
Thrombocyte count (/μL) 305.46 ± 61.94 340.36 ± 32.26 
Urea level (mg/dL) 22.68 ± 2.88 23.58 ± 3.79 
Creatinine (mg/dL) 0.66 ± 0.15 0.66 ± 0.15 
SGOT (U/L) 30.56 ± 3.32 30.88 ± 3.49 
SGPT (U/L) 31.32 ± 3.35 31.30 ± 3.27 
Note: There were no significant differences in subject characteristics (independent samples t-test, p > 0.05), indicating that the control and T1DM 
groups were appropriately matched. IBW: Ideal Body Weight. 
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Measurement of MDA 
The method of malondialdehyde measurement was 
based on the reaction of chromogenic reagents N-me-
thyl-2-phenylindole (NMPI) with MDA at 45°C as pre-
viously described.10 The procedure began by adding 10 
mL probucol to each well. After 200 µL sample and 600 
µL R1 reagent (NMPI in acetonitrile) were added, the 
sample was mixed by using a vortex. A 150- µL volume 
of hydrochloric acid was added to each well, mixed again 
by using a vortex and incubated for 60 min at 45°C. 
After incubation, the sample was centrifuged at 10,000 
rpm for 10 minutes. The supernatant was removed and 
the absorbance read at 586 nm. MDA measurements 
were conducted at the Physiology Laboratory, Medical 
Faculty of Brawijaya University, Malang. 
 
Measurement of IL-10  
IL-10 levels were measured by ELISA as described 
by the manufacturer.10 A 200-µl volume of assay diluent 
was added to each well and incubated for 1 h. After that, 
100 µl standards was added to control and sample wells, 
which were covered with an adhesive strip and then in-
cubated for 2 h at room temperature. After four washes 
with wash buffer (400 µL), 100 µL antibody was added 
to each well and incubated for 1 h. After incubation, 100 
µL avidin-horseradish peroxidase (HRP)-conjugated IL-
10 was added to each well. The microplate was then cov-
ered with an adhesive strip, incubated for 30 min at 
room temperature, and rewashed. A 100-µL volume of 
tetramethylbenzidine (TMB) substrate solution was add-
ed to each well, incubated for 30 min at room tempera-
ture, and 100 µL stop solution was added. Optical den-
sity was measured at 450 nm by using a microplate read-
er. Absorbance values were used to plot a standard curve 
and to calculate the IL-10 level in each sample. IL-10 
measurements were conducted at the Physiology Labor-
atory, Medical Faculty of Brawijaya University, Malang. 
 
Measurement of HbA1c 
Hemoglobin A1c (HbA1c) levels were measured in 
whole blood samples to which EDTA was added. A 5-
µL blood sample was mixed with 1.5 mL diluent solu-
tions before analysis. The level of HbA1c in the sample 
was measured by using a Bio-Rad D-10TM.10 HbA1c 
measurements were conducted at the Clinical Pathology 
Laboratory, Saiful Anwar General Hospital, Malang. 
 
RESULTS AND DISCUSSION 
Subject characteristics 
In this research, subjects were T1DM patients who  
routinely attended the Endocrinology Department of 
Saiful Anwar General Hospital for outpatient care dur-
ing the research period. Table 1 shows subject charac-
teristics of the two groups.  
 
SOD and MDA levels 
Results showed that both SOD and MDA levels 
were significantly different between T1DM and control 
groups (independent samples t-test, p < 0.05). SOD lev-
els in the T1DM group were significantly lower as com-
pared with control group. Conversely, MDA levels in 
the T1DM group were significantly higher as compared 
with the control group.  
 
IL-10 levels 
Results showed that the IL-10 level was significantly 
different between the T1DM and control groups (inde-
pendent samples t-test, p < 0.05). IL-10 levels in the 
T1DM group were significantly higher as compared 
with the control group. 
 
HbA1c levels 
Results showed that HbA1c levels were significantly 
higher as compared with the control group (independ-
ent samples t-test, p < 0.05).  
 
Correlation and path analysis of SOD, MDA, and IL-10 
with HbA1c levels 
Results showed that all variables were significantly 
correlated with each other. IL-10 was positively corre-
lated with SOD levels (p < 0.05, r = 0.853) and negatively 
correlated with MDA levels (p < 0.05, r = -0.866). IL-10 
was also negatively correlated with HbA1c levels (p < 
0.05, r = -0.813). SOD levels were negatively correlated 
with HbA1c levels (p < 0.05, r = -0.762). MDA levels 
were positively correlated with HbA1c levels (p < 0.05, r 
= 0.973) (Table 2). 
 
Table 2.  Levels of SOD, MDA, IL-10, and HbA1c between 
T1DM and control groups 
Variable 
Control (n = 
25) Mean ± 
SD 
T1DM (n = 25) 
Mean ± SD 
SOD (µmol/L) 384.08 ± 49.60 158.06 ± 56.87* 
MDA (µmol/L) 0.40 ± 0.12 1.69 ± 0.87* 
IL-10 (pg/mL) 53.85 ± 10.56 17.24 ± 4.14* 
HbA1c (µmol/L) 4.96 ± 0.22 10.64 ± 3.17* 
Note:  * p < 0.05 (independent samples t-test). 
 
Correlation of Interleukin-10, SOD, and MDA  
  
 
JTLS | J. Trop. Life. Science 289 Volume 7 | Number 3 | September | 2017 
Path analysis using multiple regression showed that 
IL-10, SOD, and MDA levels  simultaneously  affected 
HbA1c levels in T1DM patients by as much as 99.4%. 
Briefly, IL-10 directly increased SOD levels (R2 = 0.853) 
and directly decreased MDA levels (R2 = -0.866). IL-10 
also indirectly decreased HbA1c levels via MDA (R2 = -
0.980). 
In this study, a total of 25 subjects were included in 
each of the T1DM and control groups. There were no 
significant differences in subject characteristics between 
the two groups, indicating that the T1DM and control 
groups were appropriately matched. IL-10 levels were 
significantly lower in the T1DM group as compared 
with the control group. This result was discordant with 
a previous study, which reported that IL-10 was pro-
duced at higher levels in high-risk diabetes mellitus 
(DM) patients, suggesting an autocrine role of this cy-
tokine in islet cell destruction [5] IL-10 regulates inflam-
matory processes through suppression of proinflamma-
tory cytokines, chemokines, adhesion molecules, APC 
(antigen presenting cells), and costimulatory molecules 
in monocytes/macrophages, neutrophils, and T cells 
[12]. IL-10 has been reported to act in the phosphatidyl-
inositol 3-kinase (PI3K) and Akt/PKB (Protein Kinase 
B) pathways, whereas PI3K acts in gluconeogenesis sup-
pression and glycogen synthesis stimulation [13] The 
exogenous IL-10 administration could inhibit the pro-
gression of T1DM in NOD rats [14]. Another study 
showed that IL-10, which is produced by pancreatic Th2 
cells was not effective in protecting NOD rats from the 
onset of T1DM [15]. 
In this study, SOD levels were significantly higher 
in the control group as compared with the T1DM group. 
This result was in accordance with a previous study sug-
gesting that SOD activity in DM was inhibited [16]. Fur-
thermore, another study showed that serum superoxide 
levels were higher in 47 T1DM patients as compared 
with the control group, suggesting that oxidative stress 
was occurring in T1DM patients [17]. Another previous 
study reported that SOD, CAT, and Cp activity was de-
creased in type 1 and 2 DM as compared with the con-
trol. A lower level of SOD predicts vascular dysfunction 
in DM patients [18]. A previous study reported that 
SOD levels and activity were higher in pediatric T1DM 
patients and associated with flow-mediated dilatation. 
High SOD levels in the circulation could protect chil-
dren and adolescents with T1DM from endothelial dys-
function [19]. The highest activity of SOD was found in 
pediatric DM patients at the clinical onset of disease 
[20]. 
Superoxide anion reacts with nitric oxide to form 
reactive peroxynitrite [21]. Abundant production of su- 
peroxide anion-induced by hyperglycemia could stimu-
late protein kinase C, the hexosamine and polyol path-
ways, and the formation of advanced glycation end prod-
ucts (AGE). AGE was important in pathogenesis of DM 
complications [22, 23]. 
In this study, MDA levels were significantly higher 
in the T1DM group as compared with the control group. 
MDA as a product of lipid peroxidation was increased 
as a result of oxidative stress, and its level was elevated 
in DM patients [16, 20, 24] Furthermore, oxidative 
stress contributed to the formation of oxidized LDL and 
worsened vascular complications in DM patients [25]. 
Lipid peroxidation affects membrane function and elas-
ticity, which in turn converts enzymatic and receptor ac-
tivity and decreases membrane fluidity [26, 27]. 
In this study, glycemic control of T1DM was re-
flected in HbA1c levels. As many as 20 of 25 subjects 
(T1DM group) had poor glycemic control (HbA1c > 
7.5%). HbA1c was reflected in blood glucose concentra-
tion within 6 – 12 weeks [28, 29]. This result was in 
accordance with a previous study [16, 17, 30]. Higher 
HbA1c levels could be caused by a limited supply of in-
sulin and poor blood glucose monitoring [31]. 
A correlation study of IL-10, SOD, and MDA was 
carried out. In this study, IL-10 directly increased the 
SOD level. IL-10 played an important role in endothelial 
protection after acute inflammation induced by higher 
superoxide levels. Restoration of vasorelaxation after 
Polyethylene glycol-superoxide dismutase (PEG-SOD) 
or allopurinol administration confirmed that endothelial 
protection was likely mediated by decreased superoxide 
via xanthine oxidase [32]. A similar study showed that 
endothelial relaxation in inflammation, atherosclerosis 
and the diabetic condition was recovered by SOD ad-
ministration [33]. Furthermore, IL-10 could inhibit pro-
inflammatory cytokine production, which in turn inhib-
ited ROS production [34, 35]. 
IL-10 directly decreased MDA levels in T1DM pa-
tients. A previous study reported that micronutrient ad-
ministration could increase peripheral/lymphatic IL-4 
and IL-10, decrease blood glucose levels, increase pan-
creatic β-cell function, increase pancreatic insulin levels, 
increase GSH-Px activity, and decrease pancreatic MDA 
levels. This result indicated that micronutrients could 
decrease islet cell lesions through elevated production of 
IL-4 and IL-10 and decrease oxidative stress in diabetic 
mice, reflected in higher antioxidant levels and lower 
MDA levels [36]. 
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Results also showed that IL-10 decreased HbA1c 
levels in T1DM patients. A previous study reported that 
IFN-γ and IL-10 production in diabetic peripheral blood 
mononuclear cells were associated with metabolic con-
trol. This result indicated that good metabolic control in 
diabetic patients would improve activation and mainte-
nance of the immune response and decrease vulnerabil-
ity to infection [37]. 
Superoxide dismutase levels were negatively corre-
lated with HbA1c levels in T1DM patients in this study. 
This result was in accordance with a previous study, 
which reported that SOD, both in serum and saliva, was 
higher in diabetic patients and negatively correlated with 
glycemic control [38]. A similar study showed that total 
antioxidant capacity in diabetic patients was signifi-
cantly lower as compared with the control. Furthermore, 
in diabetic patients, there was a significant correlation 
between total antioxidant capacity and HbA1c levels, 
fasting blood glucose levels, and duration of DM. How-
ever, there was no correlation between SOD and GPx 
with those parameters as previously stated. The conclu-
sion of this study was that total antioxidant capacity 
could be used as an indicator of glycemic control and 
progression of complications [39]. Another study con-
sidered that the main factor in decreased salivary SOD 
activity was elevated glycation of this enzyme or a di-
minished effect of free radicals by a glycated protein on 
SOD activity [40].  
Malondialdehyde and HbA1c levels were signifi-
cantly correlated in this study. A previous study showed 
similar results [16]. Another study reported significant 
elevation of total cholesterol, LDL, apolipoprotein A, 
apolipoprotein B, and MDA levels in T1DM patients. 
Furthermore, serum MDA levels and the MDA/LDL in-
dex were elevated and significantly correlated with met-
abolic control in T1DM [41]. A previous study showed 
that elevated salivary and serum antioxidant levels de-
pended on HbA1c levels and the severity of diabetes. 
Moreover, MDA levels were also correlated with fasting 
plasma glucose [38]. In accordance with this study, a 
previous study also showed decreased activity of several 
antioxidant enzymes such as SOD, GPx, and CAT in 
T1DM patients, but MDA was increased significantly in 
the T1DM group relative to the control. Furthermore, 
MDA was positively correlated with HbA1c, but SOD 
was negatively correlated with HbA1c [42]. Another 
study found no correlation between MDA and glycemic 
control and found that elevation of MDA levels in 
nondiabetic patients was associated with age, periodon-
tal status, and smoking [43, 44]. 
CONCLUSION 
This study can be concluded that IL-10 and SOD 
levels were significantly decreased, but MDA and 
HbA1c levels were significantly elevated in the T1DM 
group. IL-10 levels were positively correlated with SOD 
levels and negatively correlated with MDA and HbA1c. 
SOD levels were negatively correlated with HbA1c lev-
els. MDA was positively correlated with HbA1c levels. 
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